# Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

> **NCT04308395** · PHASE3 · TERMINATED · sponsor: **Sol-Gel Technologies, Ltd.** · enrollment: 108 (actual)

## Conditions studied

- Basal Cell Nevus Syndrome

## Interventions

- **DRUG:** Patidegib Topical Gel, 2%

## Key facts

- **NCT ID:** NCT04308395
- **Lead sponsor:** Sol-Gel Technologies, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-03
- **Primary completion:** 2021-07-14
- **Final completion:** 2021-07-14
- **Target enrollment:** 108 (ACTUAL)
- **Why stopped:** Study was terminated early due to low blinded event rate and this study termination is not related to safety of the drug Patidegib Topical Gel, 2%.
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04308395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04308395, "Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04308395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*